REG - Redx Pharma plc - New Grant of Options
21/12/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221221:nRSU3943Ka&default-theme=true
RNS Number : 3943K Redx Pharma plc 21 December 2022
REDX PHARMA PLC
("Redx" or the "Company")
New Grant of Options
Alderley Park, UK, 21 December 2022 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, announces a new grant of options.
The Board has authorised the grant of additional options to Lisa Anson (Chief
Executive Officer), Richard Armer (Chief Scientific Officer), Jane Robertson
(Chief Medical Officer), Peter Collum (Chief Financial Officer), James Mead
(Chief Operating Officer) and Claire Solk (General Counsel and Company
Secretary) on 21 December 2022, all of whom are classed as persons discharging
managerial responsibility ("PDMRs") under EU Regulation 596/2014 as it forms
part of domestic law in the United Kingdom by virtue of the European Union
(Withdrawal) Act 2018, as set out further below. The options are being granted
at 56.5 pence per Ordinary Share, being the market price at the close of
business on 20 December 2022. Subsequent vesting will be subject to certain
time criteria having been met.
Name Position Number of Options Granted Vesting Date Total Options Held Following the Grant
Lisa Anson (Director/PDMR) Chief Executive Officer 1,700,000 21 December 2025 14,383,586
Richard Armer Chief Scientific Officer 900,000 21 December 2025 6,984,378
(PDMR)
Jane Robertson Chief 900,000 21 December 2025 2,700,000
(PDMR) Medical Officer
Peter Collum (PDMR) Chief Financial Officer 900,000 21 December 2025 2,700,000
James Mead Chief 600,000 21 December 2025 2,500,000
(PDMR) Operating Officer
Claire Solk General Counsel & Company Secretary 600,000 21 December 2025 1,250,000
(PDMR)
In addition, options over a further 1,000,000 Ordinary Shares of 1 pence each
will be granted on 21 December 2022 to certain other staff of the Company.
These options will also be granted at 56.5 pence per Ordinary Share, with
vesting also subject to certain time criteria having been met.
Following the grants referred to above, the Company will have granted options
over a total of 45,812,962 Ordinary Shares, representing 13.7 per cent. of the
share capital in issue. The number of options that may be awarded remains
limited such that the aggregate number of Ordinary Shares of 1p each under
option will be less than 15 per cent. of the total issued share capital of the
Company.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Lisa Anson
2. Reason for the notification
a) Position / status Chief Executive Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Grant of options under the Redx All Employee Share Option Scheme
c) Prices(a) and volume(s)
Exercise Price per Ordinary Share Volume
56.5 pence 1,700,000 Ordinary Shares
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 21 December 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
21 December 2022
f)
Place of the transaction
Outside a trading venue
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Richard Armer
2. Reason for the notification
a) Position / status Chief Scientific Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Grant of options under the Redx All Employee Share Option Scheme
c) Prices(a) and volume(s)
Exercise Price per Ordinary Share Volume
56.5 pence 900,000 Ordinary Shares
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 21 December 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
21 December 2022
f)
Place of the transaction
Outside a trading venue
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Jane Robertson
2. Reason for the notification
a) Position / status Chief Medical Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Grant of options under the Redx All Employee Share Option Scheme
c) Prices(a) and volume(s)
Exercise Price per Ordinary Share Volume
56.5 pence 900,000 Ordinary Shares
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 21 December 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
21 December 2022
f)
Place of the transaction
Outside a trading venue
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Peter Collum
2. Reason for the notification
a) Position / status Chief Financial Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Grant of options
c) Prices(a) and volume(s)
Exercise Price per Ordinary Share Volume
56.5 pence 900,000 Ordinary Shares
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 21 December 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
21 December 2022
f)
Place of the transaction
Outside a trading venue
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name James Mead
2. Reason for the notification
a) Position / status Chief Operating Officer
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Grant of options under the Redx All Employee Share Option Scheme
c) Prices(a) and volume(s)
Exercise Price per Ordinary Share Volume
56.5 pence 600,000 Ordinary Shares
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 21 December 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
21 December 2022
f)
Place of the transaction
Outside a trading venue
1. Details of the person discharging managerial responsibilities (PDMR) / person
closely associated
a) Name Claire Solk
2. Reason for the notification
a) Position / status General Counsel & Company Secretary
b) Initial notification / Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Redx Pharma plc
b) LEI 213800HMS4EBXO589Y37
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over Ordinary Shares of 1 pence each in Redx Pharma plc
Identification code ISIN for Redx Pharma plc Ordinary Shares:
GB00BSNB6S51
b) Nature of the transaction Grant of options under the Redx All Employee Share Option Scheme
c) Prices(a) and volume(s)
Exercise Price per Ordinary Share Volume
56.5 pence 600,000 Ordinary Shares
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transaction 21 December 2022
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
21 December 2022
f)
Place of the transaction
Outside a trading venue
For further information, please contact:
Redx Pharma Plc T: +44 (0)1625 469 918
UK Headquarters
Caitlin Pearson, Head of Communications
ir@redxpharma.com (mailto:ir@redxpharma.com)
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330
Claes Spång/ Satheesh Nadarajah/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, being developed as
a targeted treatment for Wnt-ligand dependent cancers, commenced a Phase 2
programme in November 2021. The Company's lead fibrosis product candidate,
the selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF)
in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing
towards a CTA/IND application at the end of 2023.
The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor
targeting fibrotic diseases including IPF, which AstraZeneca is progressing in
a Phase 1 clinical study. In addition, Redx has forged collaborations with
Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by
Redx which Jazz is now progressing through Phase 1 clinical studies, and an
early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please
visit: www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFBLLLLLLFFBZRecent news on Redx Pharma
See all newsRCS - Redx Pharma plc - Redx Reports Encouraging Zamaporvint Phase 2 Data
AnnouncementREG - AIM Redx Pharma plc - Cancellation - Redx Pharma Plc
AnnouncementREG - Redx Pharma plc - Share Purchases by a PDMR
AnnouncementREG - Redx Pharma plc - Share Purchases by PDMR’s
AnnouncementREG - Redx Pharma plc - Update on AIM Delisting
Announcement